This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
An unusual collaboration among genetherapy developers suggests certain mutations could be behind "peculiar" side effects experienced by several patients treated in clinical trials.
The US Food and Drug Administration (FDA) has granted approval for CSL Behring’s adeno-associated virus vector-based genetherapy, Hemgenix (etranacogene dezaparvovec), to treat haemophilia B (congenital Factor IX deficiency) in adult patients. Cell & GeneTherapy coverage on Pharmaceutical Technology is supported by Cytiva.
But scientists have struggled to find effective treatments for many of these diseases since the dawn of modern medicine. Recent years have seen a steadily growing number of approvals for cell and genetherapies, which has spurred on the community to continue innovating in this space. A new frontier in cancer research.
Sarepta has not provided “unambiguous evidence” its treatment can help patients, agency scientists wrote in documents released ahead of a crucial Friday advisory committee meeting.
Elsewhere, AskBio advanced a genetherapy and Pfizer hired a scientist well versed in GLP-1 science. The Swiss pharma will base cardiometabolic drug research at the new Allston site.
Credit: Professor Jane Farrar and Dr Daniel Maloney, Trinity College Dublin Scientists from Trinity College Dublin have developed a new genetherapy approach that offers promise for one day treating an eye disease that leads to a progressive loss of vision and affects thousands of people across the globe.
Merck and Synplogen have signed a non-binding Memorandum of Understanding (MoU) to expedite the development and manufacturing of viral vector-based genetherapy applications. The firms intend to merge their expertise to provide simplified viral vector genetherapy development, production and testing in Japan.
Kathy High, a scientist and executive who led the development of the first genetherapy approved in the U.S., has left Bayer subsidiary AskBio two years after joining.
Scientist Jim Wilson is synonymous with genetherapy — and for good reason. His work has generated millions of dollars for his employer, the University of Pennsylvania, and made Wilson a towering figure in the genetherapy world, with the wealth and fame to match.
Scientists have used genetherapy and a newly developed light-sensing protein to restore sight in mice: with the technology to start clinical trials in the US later this year.
Valentine — On November 22, 2022, FDA approved CSL Behring’s BLA for Hemgenix (etranacogene dezaparvovec), an AAV-based genetherapy for the treatment of adults with Hemophilia B who currently use Factor IX prophylaxis therapy, have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.
Cell and genetherapies are predicted to be the future of medical treatment by providing the body with the means to repair itself and recover from a range of serious conditions and severe diseases. Often, cell and genetherapies are spoken of as miracle treatments, yet this progress has hardly occurred overnight.
Scientists at UMass Chan Medical School have developed a technology to deliver genetherapy directly to lung tissue through intranasal administration, a development that could potentially create a new class of treatments for lung disease.
Moderna and IBM scientists will also use an AI foundation model known as MoLFormer, to predict the physical properties of a molecule and understand the characteristics of potential mRNA medicines. Cell & GeneTherapy coverage on Pharmaceutical Technology is supported by Cytiva.
Findings add safety, efficacy support for genetherapy developed at OHSU A decade after the birth of the first primates born with the aid of a genetherapy technique designed to prevent inherited mitochondrial disease, a careful study of the monkeys and their offspring reveals no adverse health effects.
University of Utah Health scientists have corrected abnormal heart rhythms in mice by restoring healthy levels of a protein that heart cells need to establish connections with one another.
Credit: RCSI Scientists have developed polypeptide-based materials that act as effective vectors for delivering genetherapies. The first-of-its-kind platform enables the vectors to be adapted to suit the specific genetherapy cargo.
Scientists and doctors at University College London Great Ormond Street Institute of Child Health (UCL GOS ICH) and Great Ormond Street Hospital (GOSH) have given hope of a genetherapy cure to children with a rare degenerative brain disorder called Dopamine Transporter Deficiency Syndrome (DTDS).
The past twelve months have culminated in an unprecedented level of excitement, investment, and clinical progress within the genetherapy field. This year’s agenda includes a novel track designed for quality control and process development groups working in genetherapy. Download the full event guide to find out more.
bluebird bio is to ask regulators to restart clinical studies of its LentiGlobin for sickle cell disease, after an investigation concluded that a case of acute myeloid leukaemia (AML) was “very unlikely” to be caused by the genetherapy. Shares in bluebird ticked up following the announcement.
Introduction Cell and genetherapy is an upcoming wave of therapeutic innovation in the healthcare and life sciences industry and is being pragmatically accepted worldwide. The genetherapy market reported its first market approvals back in 2017 and the evolution has been extensive ever since.
Claudia Zylberberg is a scientist and founder, board member and former CEO of Akron Biotech, a company that makes materials and technologies to support advanced therapy development. We spoke to her about her career, personal triumphs and candidacy for President of the International Society for Cell and GeneTherapy (ISCT),
The field of cell and genetherapies (CGT) is constantly evolving, and there has been significant progress in this area of research. However, despite the promise of these therapies, the regulations governing them lag the science, which in turn hinders the clinical translation of these novel medicines.
After spending almost an entire day deliberating the safety of Vertex Pharmaceuticals’ and CRISPR Therapeutics’ CRISPR-based genetherapy exa-cel for sickle cell disease, a US Food and Drug Administration (FDA) advisory panel appears to be satisfied with what it saw.
In late August, Pfizer announced it was investing an additional $500 million into its state-of-the-art genetherapy manufacturing facility in Sanford, North Carolina. Ricci told BioSpace the company has been “investing heavily in genetherapy and in the Raleigh-Durham Research Triangle Park area.”
But while companies continue studying allogeneic CAR-T therapies, including for their coveted use in solid tumours, such advancements remain challenging. More broadly however, several advancements are on the horizon for cell and genetherapies in 2023. AZ: Cell and genetherapies often come with a high price.
Scientists have discovered that genetherapy and the diabetes drug metformin may be potential treatments for late-onset retinal degeneration (L-ORD), a rare, blinding eye disease. The findings are published in Communications Biology.
The FDA has approved a request from American Gene Technologies to begin a clinical study into its HIV genetherapy. The treatment is being researched by scientists collaborating from American Gene Technologies, the Laboratory of Immunoregulation and the National Institute of Allergy and Infectious Diseases.
A group of scientists designed BravoAAV and ProntoLVV at AGC Biologics’ site in Milan, Italy. AGC Biologics’ global cell and gene team has so far provided support to four commercial viral vector products, three cell therapies, as well as more than 30 cell and genetherapy studies across the US and Europe.
STAT’s Jason Mast joins us to discuss Jim Wilson, a pioneering scientist synonymous with the rise of genetherapy who staffers say presided over a toxic, abusive workplace. We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast.
.
A biotech company spun out of the University of Edinburgh will utilise research to develop new genetherapies to target different types of cancer. The funding will be used to develop a pipeline of ‘highly selective’ genetherapies targeting cancer stem cells in a variety of solid tumour types.
In Nature Communications, Fred Hutch scientists demonstrate in a mouse model how genetherapy could cure an infection that afflicts billions of people Infectious disease researchers at Fred Hutchinson Cancer Research Center have used a gene editing approach to remove latent herpes simplex virus 1, or HSV-1, also known as oral herpes.
New genetic sensors, developed by scientists at University of Warwick and Keele University, could function as a lab test device and even as a live monitoring system inside living cells The innovative system can detect when a specific gene in a cell is active – instead of only detecting its presence The technology is based […].
Study in The CRISPR Journal reports the app advances CRISPR genetherapy R&D; 18-year-old software savant helped lead the app’s development Wilmington, DE, Feb. The app reveals potentially risky DNA […].
There are many treatments in the pipeline for genetic diseases, including several cell and genetherapies that present significant treatment potential. As of July 2023, the American Society of Cell + GeneTherapy stated there were 3,905 therapies in development.
The scientists analyzed samples from patients with the most common pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC). Avrobio genetherapy eradicates toxic substrate in Fabry patient. Median overall survival in those patients was 5.8 months, whereas patients without inflammation before treatment survived on average 12.3
Sanofi Research global head and chief scientific officer Frank Nestle said: “At Sanofi, we are pushing the boundaries of science by developing a diverse range of next-generation therapies based on natural killer (NK) cells, which could have broad applications across solid tumours and blood cancers.
Scientists have used genetherapy to regenerate damaged nerve fibres in the eye, in a discovery that could aid the development of new treatments for glaucoma, one of the leading causes of blindness worldwide.
To develop and commercialize them with maximum efficiency, the FDA, scientists and developers must innovate, according to panelists speaking during the Presidential Plenary on Commercialization at the International Society of Cell & GeneTherapy on May 26.
Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Source link: [link]
Following that hypothesis, scientists designed oral inhibitors, which could target mitochondrial DNA (mtDNA). Atsena raises USD 55 Million financings for blindness genetherapy. Luxturna has been authorized for LCA caused by mutations in the RPE65 gene, and another inherited retinal disease called Retinitis Pigmentosa.
Findings explain how plants use RNA to defend against fungal invaders Credit: Nicole Ward Gauthier/University of Kentucky New research reveals an essential step in scientists’ quest to create targeted, more eco-friendly fungicides that protect food crops. However, their pivotal roles […].
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content